02 November 2017 : Clinical Research
Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
Hong Shi1ABCDEF, Zongping Han2ABCDEF, Jian Liu2BCDE, Jinfang Xue2B, Shuya Zhang3B, Zhe Zhu4DEF, Jinyu Xia2D, Mingxing Huang2ABCDEFG*DOI: 10.12659/MSM.903382
Med Sci Monit 2017; 23:5230-5236
Abstract
BACKGROUND: The antiviral effect of HBV in different nucleos (t) ide analogues is still not well known. This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA.
MATERIAL AND METHODS: The effective data of 207 patients treated by LMV (n=43), ADV (n=57), LdT (n=54) or ETV (n=53) were collected and analyzed during 144-week follow-up by retrospective analysis.
RESULTS: Serum HBV DNA levels were significantly lower in the ETV group 1.91±0.45 log10 IU/ml) than in the LdT group (2.09±0.62 log10 IU/ml), ADV group (2.26±0.73 log10 IU/ml), and LMV group (2.08±0.75 log10 IU/ml) at 12 weeks (P=0.0464). HBV DNA levels were maintained at lower levels in the ETV group compared to other 3 groups during follow-up (48 weeks, P<0.001; 96 weeks, P<0.001). Multivariate Cox regression analysis showed that LMV (P=0.001), ADV, (P<0.001), and LdT (P<0.001) were all negative predictors of HBV DNA-negative time, but ETV was not. Viral breakthrough occurred in 34.8% (15/43) of patients in the LMV group; 5.26% (3/57) in the ADV group, 7.4.0% (4/54) in the LdT group, and 0% (0/53) in the ETV group at the end of follow-up. No significant differences were found in mean ALT levels (all P>0.05) or in cumulative normalization rates (P=0.473).
CONCLUSIONS: ETV was more potent and faster for viral response and lower viral breakthrough in medium load of HBV DNA when compared to LMV, ADV, or LdT monotherapy in HBeAg-negative CHB.
Keywords: Hepatitis B, Hepatitis, Chronic, Lamivudine
Editorial
01 August 2022 : Editorial
Editorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 PandemicDOI: 10.12659/MSM.937927
Med Sci Monit 2022; 28:e937927
In Press
12 Aug 2022 : Clinical Research
Risk Factors and Pathogen Spectrum in Continuous Ambulatory Peritoneal Dialysis-Associated Peritonitis: A S...Med Sci Monit In Press; DOI: 10.12659/MSM.937112
11 Aug 2022 : Meta-Analysis
Optimal Surgical Treatment Method for Anterior Cruciate Ligament Rupture: Results from a Network Meta-AnalysisMed Sci Monit In Press; DOI: 10.12659/MSM.937118
10 Aug 2022 : Review article
Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and NecroptosisMed Sci Monit In Press; DOI: 10.12659/MSM.937766
10 Aug 2022 : Database Analysis
Use and Effects of Augmentation of Labor with Oxytocin: A Single-Center, Retrospective, Case-Control Study ...Med Sci Monit In Press; DOI: 10.12659/MSM.937557
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996